Intervention of Edaravone Dexborneol on Iron Metabolism in Perihematomal Brain Tissue of Rats with Intracerebral Hemorrhage and its Neuroprotective Mechanism

INTRODUCTION: Cerebral hemorrhage is highly disabling and lethal and is poorly treated. Previous studies have shown that edaravone dexborneol has effectively treated ischemic strokes. However, its use in treating cerebral hemorrhage has not been reported. MATERIALS AND METHODS: 128 SD rats were randomly divided into the sham-operated group, cerebral hemorrhage group, edaravone intervention group (6 mg/kg), and edaravone dexborneol intervention group (7.5 mg/kg). All were administered by intraperitoneal injection two times until execution. Rats in each group were scored for neurological function at each time point after modeling and drug administration according to the Garcia scale. RESULTS: Compared with the cerebral hemorrhage group, the brain tissue damage around the hematoma was significantly reduced in the edaravone intervention group. The edaravone dexborneol intervention group at each time point and the expression of Fpn-1 protein were significantly higher (P < 0.05, P < 0.01), and the expression of ROS content, TfR, and IRP-2 was significantly lower (P < 0.05, P < 0.01); the changes in the edaravone dexborneol intervention group than the edaravone intervention group were more significant (P < 0.01). CONCLUSION: Edaravone dexborneol may play a cerebral protective role by regulating the expression of iron metabolism-related proteins in rats with cerebral hemorrhage and inhibiting iron death in neuronal cells.